Since childhood, Rachael Petersen had lived with an unexplainable sense of grief that no drug or talk therapy could entirely ease. So in 2017 she volunteered for a small clinical trial at Johns Hopkins University that was testing psilocybin, the active ingredient in magic mushrooms, for chronic depression. “I was so depressed,” Petersen, 29, said… Read More »
Temporary hearing loss can affect anyone, but it’s most likely to impact people who have been exposed to recent loud noises or have a bad cold and ear infection. Most of the time, the hearing loss will go away quickly (in a day or two). If it doesn’t, you should seek medical care. Is it one ear… Read More »
The Food and Drug Administration (FDA) has approved Emgality (galcanezumab-gnlm; Lilly) for injection for the treatment of episodic cluster headache in adults. The approval was based on the results from a phase 3 double-blind, placebo-controlled trial that included 106 patients diagnosed with episodic cluster headaches. Patients were randomized to receive either once-monthly Emgality 300mg administered… Read More »
FDA Approves Nayzilam (midazolam) Nasal Spray to Treat Seizure Clusters Print this page Brussels (Belgium) & Atlanta, Georgia (U.S.) – May 20 2019: UCB announced today that the U.S. Food and Drug Administration (FDA) has approved a New Drug Application for the company’s newest anti-epileptic drug (AED) Nayzilam (midazolam) nasal spray CIV, a benzodiazepine indicated… Read More »